ution; (b) preparing an aqueous phase containing a surface modifying agent; and (c) spraying the solution into the aqueous phase, substantially as disclosed in the same above-cited International Patent Publication No. Wo 97/14407. [0303] Patent and other literature relating to drug nanoparticle compositions teaches that, in general, the smaller the drug particle size, the greater is the advantage